

國立成功大學

114學年度碩士班招生考試試題

編 號：194

系 所：臨床藥學與藥物科技研究所

科 目：調劑學

日 期：0211

節 次：第 1 節

注 意：1.不可使用計算機
2.請於答案卷(卡)作答，於
試題上作答，不予計分。

Answer the following questions

1. Follow the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, which state that the primary goals of therapy are to alleviate patient symptoms, reduce exacerbations, and enhance patient function and quality of life. What are the initial pharmacologic agents selected based on the severity of symptoms and the risk of future exacerbations? (20%)
2. What are the primary indications for the drugs listed below, and which require dosage adjustments based on renal function: amiodarone, atorvastatin, denosumab, empagliflozin, famotidine, linagliptin, and ticagrelor? (20%)
3. How is drug-induced Fanconi syndrome evaluated, and how should these events be managed? (20%)
4. SGLT2 inhibitor-related euDKA (euglycemic diabetic ketoacidosis) is a preventable adverse event. Describe two preventive strategies that can be implemented in clinical practice, including selecting eligible patients for SGLT2 inhibitor use and reducing risk factors. (20%)
5. Total parenteral nutrition (TPN) provides nutrition intravenously for patients whose gastrointestinal tract is inaccessible. What are the basic components and additives in TPN? (10%)
6. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are global health challenges of epidemic proportions. What is the role and impact of clinical pharmacy services for these patient populations? (10%)